demo · 741 papers with claims · 599 for outreach · 61 old · 81 reviews
<2016
Filtered out
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties
Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non
Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodi
Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (
Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial
Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute L
A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid L
Preclinical Development of Inducible MyD88/CD40 (iMC)-Enhanced Chimeric Antigen Receptor Natural Killer (GoCAR-NK) Cells
A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatmen
Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical
Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma
Optimizing Commercial Manufacturing of Tisagenlecleucel for Patients in the US: A 4-Year Experiential Journey
FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricid
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufac
Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cel
Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Tha
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Ch
Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma
Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophen
SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL
Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia
Induced Pluripotent Stem Cell-Derived Gamma Delta CAR-T Cells for Cancer Immunotherapy
Preclinical Evaluation of Prgn-3007, a Non-Viral, Multigenic, Autologous ROR1 Ultracar-T ® Therapy with Novel Mechanism
Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain
Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CA
Duvelisib Promotes Mitochondrial Fusion and Epigenetic Reprogramming to Drive Therapeutic T Cell Persistence and Functio
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated B
Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-C
Nanoporous Substrates to Advance CAR-T Cell Production for Advanced Cell Therapies
Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogene
API-192, an Allogeneic CD19/20 CAR-NKT Cell Product Derived from Cord Blood CD34+ HSPCs for the Treatment of B-Cell Mali
Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Recep
Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma f
Manufacturing, Characterization and Anti-Tumor Activity of Allogeneic CD19-CAR Cytokine-Induced Killer (CIK) Cells Engin
CAR-T cell expansion platforms yield distinct T cell differentiation states.
Lymph-Node Inspired Hydrogels Enhance CAR Expression and Proliferation of CAR T Cells
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
CAR T‐cell therapy of solid tumors
Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis i
Natural killer cells in antitumour adoptive cell immunotherapy
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rapid manufacturing of non-activated potent CAR T cells
Engineering the next generation of cell-based therapeutics
Expanding access to CAR T cell therapies through local manufacturing
Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immu
Nutrients: Signal 4 in T cell immunity
Spheroid Coculture of Hematopoietic Stem/Progenitor Cells and Monolayer Expanded Mesenchymal Stem/Stromal Cells in Polyd
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primar
Exploring synthetic immunity: From boutique to global
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
Cytokines in the Treatment of Cancer
High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions.
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Aut
- **DOI:** 10.1093/jas/skab235.680 - **Authors:** S. H. White-Springer - **Year:** 2021 - **Journal:** Journal of Animal
EXTH-56. Optimizing CAR T cell therapy for pediatric glioma: Enhancing persistence and efficacy with DNA methylation inh
Predictive modeling of T-cell expansion: leveraging morphological metrics with invitrogen attune cytpix flow cytometer f
SAXS‐enabled Macromolecular Engineering at SIBYLS
EXTH-62. Epigenetic priming with DNMT inhibitors enhances CAR T-Cell efficacy in pediatric brain tumors
IMMU-05. TARGETING THE DYSREGULATED DNA METHYLOME DURING CAR T CELL MANUFACTURING IMPROVES THEIR FITNESS IN IMMUNOCOMPET
TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes
Antigen-specific stimulation and expansion of CAR-T cells using membrane vesicles as target cell surrogates
A Novel Generative Mycobacterium Tuberculosis-Specific T Cells Method for Adoptive Cellular Therapy
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cance
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic ca
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/r
Phase 1 study of DK2
Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices.
Technological and Manufacturing Innovation Drive Improved Access to Engineered T Cell Therapies
Worth the switch? Enhancing process performance for cell therapy manufacturing with an animal component-free raw materia
Using serum-free media to streamline and optimize CAR T-cell manufacturing workflows
The cell therapy industrial revolution: current successes, existing challenges, and expansion into new domains
Enhancing CAR-T therapy development: harnessing cell selection flexibility
New technologies to improve CAR T cell generation and biomanufacturing will lead to safer, more therapeutically effectiv
Metabolic Regulation of CAR T Cell Function by the Hypoxic Microenvironment in Solid Tumors
Advancing NK Cell Therapies: Expansion and Activation for Next-Generation Immunotherapy
Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
Ex Vivo Expansion of Highly Cytotoxic Natural Killer Cells Using Optimal Culture Medium
Cytokine Profile Following Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancie
New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?
Heme Attenuates T Cell Exhaustion and Drives Effector Function: Implications for Immune and Adoptive T Cell Therapy
Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodi
Varnimcabtagene Autoleucel (IMN-003A): Differences in T Cell Subset Phenotype in B-ALL and B-NHL Cohorts Did Not Influen
As Fast As We Can: Rational Design of Rapid Chimeric Antigen Receptor T Cell Manufacturing
Breaking Barriers in B-Acute Lymphoblastic Leukemia Treatment: Experience of a Tertiary Hospital with the Use of a Tande
Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in
Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Ce
Clinical Response after Allogeneic CAR T Cell Therapy Is Linked to Expansion of Identical CD8+ Effector-like T Cell Clon
Venetoclax Pre-Treatment of CLL/SLL Patients Enhances Autologous CAR T-Cells Efficacy
Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the
Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration
Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
Enhancing CAR-T Therapy in CLL By Modulating the Immunosuppressive Tumor Microenvironment: A Novel Approach with Signifi
Modulating the Vasoactive Intestinal Peptide (VIP) Pathway Reprograms Superior CAR T Cells
iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Effic
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-V
In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted
A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment
A Phase 1 Study of NKX019, an Allogeneic Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy in Patients with
iPSC-derived, multiplex-engineered CD8αβT cells deliver antigen-specific, potent, and durable tumor cytotoxicity without
Short-term IL-21 and GSK-3β inhibition enriches stem-like CD8⁺ T cells and boosts CD19 CAR T-cell effector function
Pharmacologic drugging of BCL-2 during manufacturing restores T cell fitness and enhances CART efficacy
CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia
A first-in-primate In Vivo CRISPR/Cas9 screen in a rhesus macaque model identifies drivers of CAR-T expansion, tissue tr
Dasatinib enhances potency of a novel CD123 CAR against AML by improving cell fitness
- **DOI:** 10.1158/2326-6074.tumimm24-a024 - **Authors:** Alok Kumar, Dayana B. Rivadeneira, Alison Kohan, Greg M. Delgo
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Aphere
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
Deterministic Lateral Displacement: The Next-Generation CAR T-Cell Processing?
Optimizing T-cell receptor gene therapy for hematologic malignancies
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell
Improved Expansion and Function of CAR T Cell Products from Cultures Initiated at Defined CD4:CD8 Ratios
Human Pluripotent Stem Cell-Derived Blood Cells for Therapies
Interleukin 21 Enhances Survival and Expansion of CAR T Cells Via Inhibition of Their Terminal Differentiation during In
Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphob
Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T
Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells
Title Point-of-Care Production of CD19 CAR-T Cells in an Automated Closed-System: Report of First Clinical Experience
Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Rec
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Use of Multi-Omics Approach to Produce a Robust Serum-Free Media for the Expansion of T Cells
Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Rece
A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lympho
Enhancing Human NK Cell Function and Specificity for Cancer Immunotherapy
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity
FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the
Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy
Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous
Next Generation NKG2D-based CAR T-cells (CYAD-02): Co-expression of a Single shRNA Targeting MICA and MICB Improves Cell
Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates
Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study o
Abstract 960: Defined cell composition and precise control over JCAR017 dose enables identification of relationships bet
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autolo
Abstract 2327: Same day transduction andin vivoexpansion of chimeric antigen receptors and synthetic driver constructs f
- **DOI:** 10.1158/1538-7445.am2019-lb-072 - **Authors:** Christopher N. Johnson, H. Senior, N. Jesuraj - **Year:** 2019
Abstract 3523: A high-throughput screening strategy for the identification of novel lymphoproliferative elements
Abstract CT118: CARPETS: A Phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimer
Abstract 3252:OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell anti-tumor efficac
Abstract 6593: PRGN-3005 UltraCAR-T™: multigenic CAR-T cells generated using non-viral gene delivery and rapid manufactu
Abstract 2821: Incorporation of intrinsic checkpoint blockade enhances functionality of multigenic autologous UltraCAR-T
Abstract 555: Allogeneic Natural Killer cells engineered to express HER2 CAR, Interleukin 15 and TGF beta dominant negat
- **DOI:** 10.1158/1538-7445.am2022-2849 - **Authors:** Jessica Walls, Y. Kam, N. Romero - **Year:** 2022 - **Journal:**
Abstract 1128: Lineage tracing of CAR T cells in patients with B cell malignancies
Abstract 5609: Investigating the undifferentiated pleomorphic sarcoma microenvironment through cytokine profiles of prim
Abstract 3606: Lenalidomide switch control of CAR T-cell phenotype and function via degradable membrane-bound IL-7
- **DOI:** 10.1158/1538-7445.am2023-1775 - **Authors:** V. Alonso-Camino - **Year:** 2023 - **Journal:** Cancer Research
Abstract 4096: Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen r
Abstract 2916: CAR-NK cells generated with CAR-RNA-LNP express high cytotoxic activity against tumor cells
Abstract 1781: G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cel
Abstract CT522: Feasibility and safety of a novel CD19 CAR T cell therapy in adults with R/R B-NHL
Abstract 4087: Co-expression of membrane bound IL-15 enhanced anti-tumor response of CAR-T
Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneall
Abstract 4108: Transient epigenetic reprogramming enhances T-cell proliferation and tumor clearance
Abstract 35: In situ CAR T cell engineering using lipid nanoparticles for B cell lymphoma therapy
Abstract 5254: The “off-the-shelf ”CD19-CAR-Vδ1T cells demonstrated an enhanced therapeutic effect on B-cell malignancy
- **DOI:** 10.1158/1538-7445.am2024-5252 - **Authors:** Vanesa Alonso-Camino, William Mirsch - **Year:** 2024 - **Journa
Abstract 6325: Lineage tracing defines responding CAR T cells in patients with B cell malignancies
Abstract 6121: A novel allogeneic anti-DLL3 CAR-NK cell therapy in treating small cell lung cancer
Abstract 6328: Preclinical development of CAR T cells with antigen-inducible IL-18 enforcement to treat GD2-positive sol
Abstract LB074: Preclinical development of API-192: An engineered CAR-NKT allogeneic cell therapy targeting CD19 and CD2
Abstract 4808: Physiological manufacturing conditions enhance in vivo efficacy of CD19 CAR T cells in mice
Abstract 6311: From bench to bedside: GMP manufacturing and testing of an LGR5-targeting CAR-T against colorectal cancer
Abstract IA019: Tumor microenvironment modulation is critical for cellular immunotherapy efficacy
Abstract 7265: Using PBMC-humanized mice to identify optimal autologous CAR T products for maximized efficacy and minimi
Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.
- **DOI:** 10.1158/1538-7445.sabcs18-1209 - **Authors:** Zhaoping Liu, Andrea Donart-Gomez, John O’Rourke - **Year:** 20
Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) wit
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race ag
Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepato
Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumo
Engineered T-cell Receptor T Cells for Cancer Immunotherapy
FOXO1 inhibition generates potent non-activated CAR T cells against solid tumors.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors.
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinic
Abstract A025: Eradication of neuroblastoma by T-cells redirected with an optimized GD2-specific chimeric antigen recept
Abstract B009: Developing a platform for CEA-directed CAR-NK cells expressing IL-15 and CCL21 for the treatment of non-s
Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor.
Abstract A043: Anti-CD19 CAR T-cells with a CRISPR/Cas9-mediated T-cell receptor knockout show high functionality in the
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
Chimeric PD-1 receptor redirects primary T cells against childhood solid tumors but not to PD-1 ligand-positive CD80-coe
The Impact of Various Cellular Product Characteristics on the Efficacy of Anti-CD19 Therapy with T-Lymphocytes Modified
Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins
Optimization of human T cell activation and expansion protocols improves efficiency of genetic modification and overall
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Rece
Low intensity vibration increases proliferation in human primary T cells: a non-invasive strategy to reduce “vein-to-vei
T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function
Precise control of immune modulation using DNA scaffold-mediated biomaterial functionalization
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods
Postprandial changes to systemic metabolism imprint durable changes on T cell immune responses
CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15– and IL-21–Driven NK Cell Proliferation
T cell functional phenotyping on a single cell scale using hydrogel microparticles.
Revolutionary Selection, Activation, and Expansion with Microbubbles for CAR-T Cell Manufacturing
Novel Workflow for Activation and Expansion of T Cells Using Microbubble Technology
Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors
Optimization of methods for peripheral blood mononuclear cells isolation and expansion of human gamma delta T cells
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
High-Content CD14+ Cells in Apheresis Products negatively affects the Transduction and Expansion of CAR T cells during L
High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17+IL-10+ Memory CD4+ T Cell Response towards a Single IL-10–Producing P
Fueling chimeric antigen receptor T cells with cytokines.
Platelet lysate boosts transgene levels and maintains undifferentiated T cell subtypes following lentiviral delivery to
A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiat
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Pha
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondeca
CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activi
Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma
IMV101, a novel CD19-targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinica
Synergistic enhancement of γδ T cell cytotoxicity against tumor spheroids through B7H3 CAR and zoledronate sensitization
More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy
New class of dual agonistic T-cell engagers for the in-patient activation and expansion of v delta 1 T cells with broad
Pre-clinical characterization and process development of a BCMA-directed CAR NK-cell therapy product for relapsed/refrac
A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-ax
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VI
Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies.
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma
CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable M
Production of Anti-CD19 CAR T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With
CAR-T Cell Production Using the Clinimacs® Prodigy System
Generating Antigen‐Specific Regulatory T Cells in the Fast Lane
Expansion deficiency of CAR‐T cells in patients with lymphoma and resolution by T cell purification
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Cell therapies for trauma and critical care medicine: critical issues in translation for cellular and novel therapies in
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.
Enhanced T cell effector activity by targeting the Mediator kinase module
CAR T cells for brain tumors: Lessons learned and road ahead
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblasti
Impact of cellular composition and T‐cell senescence of mononuclear cell concentrates on the manufacturing process of ch
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen recept
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell
P09.08 Clinical-grade manufacturing of ROR1 CAR T cells using a novel virus-free protocol
TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclini
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
164 AgenT-797, a novel allogenic and ‘off-the shelf’ iNKT cell therapy promotes effective tumor killing
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy
830 Targeting cellular senescence to increase CAR-T cell fitness
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leuk
Large-scale manufacturing and characterization of CMV-CD19CAR T cells
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
117 Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and sy
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxiciti
210 A novel medium for increased cytotoxicity and serum-minimal ex vivo expansion of natural killer (NK) cellular immuno
Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for g
CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term re
CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype.
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppresso
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metas
330 Redirecting glucose usage during in vitro expansion improves the in vivo persistence and function of adoptive T cell
344 Comparative assessment of product quality attributes associated with production of chimeric antigen receptor T cells
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chime
Natural Killer Cells: From Innate to Adaptive Features
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma
T Cell Exhaustion and CAR‐T Immunotherapy in Hematological Malignancies
In vitro high expansion of chimeric antigen receptor (CAR)-T cells in serum-free process conditions
Title: Glypican-3-specific CAR T cells co-expressing IL15 and IL21 have superior expansion and antitumor activity agains
Impact of Serum/Xeno-Free Medium and Cytokine Supplementation on CAR-T Cell Therapy Manufacturing in Stirred Tank Biorea
Oral Injections Tested in Proof-of-Concept Trial.
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Demonstrating the Manufacture of Human CAR‐T Cells in an Automated Stirred‐Tank Bioreactor
Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy
Unsupervised Machine Learning‐Based Process Analytical Tools for Near Real‐Time Cell Morphology Analysis During CAR‐T Ce
TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation
A digital shadow of CAR T cell expansion in a perfusion bioreactor: Informing optimal harvest times for autologous cell
Changes to culture pH and dissolved oxygen can enhance chimeric antigen receptor T-cell generation and differentiation.
Establishing a scalable perfusion strategy for the manufacture of CAR‐T cells in stirred‐tank bioreactors using a qualit
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients
Immunotherapy in lymphoma
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy
CAR T cell therapy in advanced B‐ALL with heavy disease burden
Synergistic effect and molecular mechanism of PVA and UM171 in ex vivo expansion of primitive hematopoietic stem cells
Drug target validation in primary human natural killer cells using CRISPR RNP
CAR T cells: Building on the CD19 paradigm
Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
Antigen-specific stimulation and expansion of CAR-T cells using membrane vesicles as target cell surrogates
CAR-T Cell Expansion in a Xuri Cell Expansion System W25.
Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
Platforms for Clinical-Grade CAR-T Cell Expansion.
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced i
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell
Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
Memory T cells: strategies for optimizing tumor immunotherapy
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering
CAR-NK cells: A promising cellular immunotherapy for cancer
Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy
Manufacturing chimeric antigen receptor T cells: issues and challenges
Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of C
Generating natural killer cells for adoptive transfer: expanding horizons
Abstract 2296: Inhibition of the PI3K/Akt pathway during CAR T cell production results in enhanced efficacy across multi
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antige
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-9863
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis
CAR T-cell therapy in multiple myeloma: more room for improvement
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
CAR-T cells: the long and winding road to solid tumors
CAR-T cell therapy: current limitations and potential strategies
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with lat
Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Driving cars to the clinic for solid tumors
Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplan
Synthetic cytokine receptors transmit biological signals using artificial ligands
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR st
A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against mul
The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Enhancing CAR-T cell functionality in a patient-specific manner
Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy
Potentiating adoptive cell therapy using synthetic IL-9 receptors
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Deconvolution of clinical variance in CAR-T cell pharmacology and response
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a p
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 tri
Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding
Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells
Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality
convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
Mapping real-time metabolic kinetics of expanded CAR T cells using hyperpolarized 13C-glucose and metabolomics
In vitro encapsulation and expansion of T and CAR-T cells using 3D synthetic thermo-responsive matrices
Asparagine restriction enhances CD8+ T cell metabolic fitness and antitumoral functionality through an NRF2-dependent st
Enhanced functionality of low-affinity CD19 CAR T-cells is associated with activation priming and a polyfunctional cytok
CD62L-selected umbilical cord blood universal CAR T cells
Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Immunotherapy for Dogs: Running Behind Humans
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies
Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suici
GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cel
Inflammatory Cytokines Regulate T-Cell Development from Blood Progenitor Cells in a Stage and Dose-Specifc Manner
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System
L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy
The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vi
Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memo
Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cance
Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Pha
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple My
Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer
HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-the-Shelf” Immunotherapy
Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored
Tr1 Cells as a Key Regulator for Maintaining Immune Homeostasis in Transplantation
Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer
Regulatory T Cells in GVHD Therapy
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells
Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future
PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononu
CXCR6 expressing T cells: Functions and role in the control of tumors
Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relap
In vitro immunotherapy potency assays using real-time cell analysis
GM-CSF perturbs cell identity in mouse pre-implantation embryos
Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and functio
PD1 blockade enhances cytotoxicity of <i>in vitro</i> expanded natural killer cells towards myeloma cells
Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty tran
Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Clinical Application of Cytokines in Cancer Immunotherapy
Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells
Preclinical development of a protocol for the manufacturing of anti-CD5 CAR-T lymphocytes for the treatment of T-lineage
Comparative characterization of the cell composition and functional properties of anti-CD19 biomedical cell products man
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in ‘off the shelf’ chimeric antigen
Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression wi
Analytical and computational studies predict negligible risk of cell death from eddy generation off flat surfaces in cel
Piloting a scale-up platform for high-quality human T-cells production
Tailored Cytokine Optimization for ex vivo Culture Platforms Targeting the Expansion of Human Hematopoietic Stem/Progeni
Optimising and adapting perfusion feeds in serum-free medium to intensify CAR-T cell expansion in stirred-tank bioreacto
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Develo
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Improving CAR T-Cell Persistence
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities.
CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine rel
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Transient stimulation expands superior antitumor T cells for adoptive therapy
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells
Recent Advances in CAR-Based Solid Tumor Immunotherapy
IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells
Investigation of the Impact from IL-2, IL-7, and IL-15 on the Growth and Signaling of Activated CD4+ T Cells
Interleukin 15 in Cell-Based Cancer Immunotherapy
The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
CAR T-Cell Therapy in Hematological Malignancies
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
Upregulation of the TCA Cycle and Oxidative Phosphorylation Enhances the Fitness of CD99 CAR-T Cells Under Dynamic Culti
CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells
Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-T
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial
Membrane Applications in Autologous Cell Therapy
A Microfluidic-Based Sensing Platform for Rapid Quality Control on Target Cells from Bioreactors
The efficacy of third generation anti‑HER2 chimeric antigen receptor T�cells in combination with PD1 blockade against ma
Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells
CAR-T CELL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A PROMISING IMMUNOTHERAPY APPROACH
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture me
CAR-T cell combination therapy: the next revolution in cancer treatment
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Challenges and new technologies in adoptive cell therapy
Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights a
Natural Killer Cells: Development, Maturation, and Clinical Utilization
CAR-NK Cells: From Natural Basis to Design for Kill
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Emerging Strategies in TCR-Engineered T Cells
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical a
Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Fluid shear stress enhances T cell activation through Piezo1
Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunoth
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
Targeting the RNA m6A modification for cancer immunotherapy
The journey of CAR-T therapy in hematological malignancies
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
Evolution of cell therapy for renal cell carcinoma
Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors
Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunot
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics
Exhaustion of CAR T cells: potential causes and solutions
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer
Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia
Natural killer cells: a promising immunotherapy for cancer
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymph
The synergistic and enhancive effects of IL-6 and M-CSF to expand and differentiate functional dendritic cells from huma
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory a
NK cell-based cancer immunotherapy: from basic biology to clinical development
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Engineering better chimeric antigen receptor T cells
CAR-NK cells for cancer immunotherapy: from bench to bedside
Strategies to enhance CAR-T persistence
Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using qCART, the Quantum pBac-based CAR-T system
Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy
Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whol
Genome-wide CRISPRa screens nominate modulators of CAR T cell survival within distinct tumor cytokine milieus
Gene editing of CD3 epsilon gene to redirect regulatory T cells for adoptive T cell transfer
RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy
Engineering CD3 Subunits with Endoplasmic Reticulum Retention Signal Facilitates Allogeneic CAR T Cell Production
Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy
Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma Therapy
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma
Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increas
An inherent T cell-activating mRNA delivery platform for in vivo CAR T generation
A Transient Immunostimulatory Niche Synergizes Adoptive and Endogenous Immunity for Enhanced Tumor Control
Dynamic estimation of metabolic state during CAR T cell production and the relationship of early metabolism to final the
Antigen-scaffolds drive preferential expansion of functional genetically engineered CAR and TCR T cells
Cytokines in Cancer Immunotherapy
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Challenges of NK cell-based immunotherapy in the new era
GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma i
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Biology and clinical application of CAR T cells for B cell malignancies
Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future pros
Impact of Manufacturing Procedures on CAR T Cell Functionality
Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
CAR-T Cell Performance: How to Improve Their Persistence?
Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives
Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation,
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
From bench to bedside: the history and progress of CAR T cell therapy
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes
Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and alloge
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients
Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy
A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in
Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells
Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024
IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and
Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion a
The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits
Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications fo
TCR-T Immunotherapy: The Challenges and Solutions
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Base
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Research progress of interleukin-15 in cancer immunotherapy
Assessing the Future of Solid Tumor Immunotherapy
Mechanisms of Resistance to NK Cell Immunotherapy
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific
3D Culture Systems for Exploring Cancer Immunology
Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiti
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
NK Cell Therapy: A Rising Star in Cancer Treatment
Recent Advances and Challenges in Cancer Immunotherapy
Role of CAR T Cell Metabolism for Therapeutic Efficacy
Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expre
Comparative analysis and process optimization for manufacturing CAR-T using the PiggyBac system derived from cryopreserv
Dexamethasone Enhances CAR T Cell Persistence and Function by Upregulating Interleukin 7 Receptor
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and canc
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Mat
Scalable CAR-T production in a 2-litre perfusion stirred-tank bioreactor with automated harvesting and scale-down model